{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T19:44:03Z","timestamp":1777059843563,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Research Centre Egypt"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Chronic inflammation and its control are crucial to the responses of glomerular and renal tubular cells. This contributes to the pathogenic mechanisms and advancement of the disease in Alport syndrome. The study aimed to elucidate the role of cyclooxygenase-2, Interleukin 4, Plasminogen activating inhibitor 1, and Prostaglandin E2 in the development and course of Alport syndrome.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>In our study inflammatory markers were evaluated in 26 Alport syndrome patients, 15 males and 11 females and 24 controls.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Their age ranged from 4 to 16 years (mean\u2009\u00b1\u2009SD was 8.50\u2009\u00b1\u20092.877) and 24 were normal controls matching age and sex. The serum levels of cyclooxygenase-2, Prostaglandin E2, Interleukin 4, and Plasminogen activating inhibitor 1 were evaluated in all patients. The serum level of cyclooxygenase-2, Prostaglandin E2, Interleukin 4, and Plasminogen activating inhibitor 1 were all increased significantly in the Alport syndrome patients compared to control (588.68\u2009\u00b1\u200973.08, 42.57\u2009\u00b1\u20094.18, 42.32\u2009\u00b1\u20093.49, and 846.47\u2009\u00b1\u200945.433, respectively versus controls (369.12\u2009\u00b1\u200950.28, 25.52\u2009\u00b1\u20094.98, 28.89\u2009\u00b1\u20093.19, and 312.79\u2009\u00b1\u200940.53 respectively).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The role of inflammatory markers cyclooxygenase-2, Prostaglandin E2, Interleukin 4, and Plasminogen activating inhibitor 1 in Alport syndrome that are causally connected and have a role in the development and course of Alport disease was delineated. This may highlight and speculate an innovative strategy for targeting the creation of safe and efficient anti-inflammatory treatments to inhibit disease progression in Alport syndrome.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12887-025-05412-2","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T04:52:27Z","timestamp":1737694347000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The role of cyclooxygenase-2 (COX-2) and inflammatory markers in the progress of Alport syndrome in Egyptian children"],"prefix":"10.1186","volume":"25","author":[{"given":"Moushira","family":"Zaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisham A.","family":"Orban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A.","family":"Shahba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rehab S. I.","family":"Moustafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Adel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatina I.","family":"Fadel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abeer","family":"Selim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hala T.","family":"El-Bassyouni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman R.","family":"Youness","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"issue":"10","key":"5412_CR1","first-page":"e47129","volume":"15","author":"A Adone","year":"2023","unstructured":"Adone A, Anjankar A. Alport syndrome: a comprehensive review. Cureus. 2023;15(10):e47129.","journal-title":"Cureus"},{"issue":"3","key":"5412_CR2","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/MNH.0000000000000983","volume":"33","author":"P Puapatanakul","year":"2024","unstructured":"Puapatanakul P, Miner JH. Alport syndrome and Alport kidney diseases - elucidating the disease spectrum. Curr Opin Nephrol Hypertens. 2024;33(3):283\u201390.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"5","key":"5412_CR3","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.xkme.2020.05.014","volume":"2","author":"BA Warady","year":"2020","unstructured":"Warady BA, Agarwal R, Bangalore S, Chapman A, Levin A, Stenvinkel P, Toto RD, Chertow GM. Alport syndrome classification and management. Kidney Med. 2020;2(5):639\u201349.","journal-title":"Kidney Med"},{"issue":"13","key":"5412_CR4","doi-asserted-by":"publisher","first-page":"7276","DOI":"10.3390\/ijms23137276","volume":"23","author":"AM Gomes","year":"2022","unstructured":"Gomes AM, Lopes D, Almeida C, Santos S, Malheiro J, Lousa I, Caldas Afonso A, Beir\u00e3o I. Potential renal damage biomarkers in Alport syndrome-a review of literature. Int J Mol Sci. 2022;23(13):7276. https:\/\/doi.org\/10.3390\/ijms23137276. PMID: 35806283; PMCID: PMC9266446.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5412_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.5049\/EBP.2008.6.1.35","volume":"6","author":"GH Kim","year":"2008","unstructured":"Kim GH. Renal effects of prostaglandins and cyclooxygenase-2 inhibitors. Electrolyte Blood Press. 2008;6(1):35\u201341.","journal-title":"Electrolyte Blood Press"},{"issue":"14","key":"5412_CR6","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.2174\/1381612053764922","volume":"11","author":"HF Cheng","year":"2005","unstructured":"Cheng HF, Harris RC. Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors. Curr Pharm Des. 2005;11(14):1795\u2013804.","journal-title":"Curr Pharm Des"},{"issue":"3\u20134","key":"5412_CR7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.prostaglandins.2011.11.004","volume":"98","author":"A Rios","year":"2012","unstructured":"Rios A, Vargas-Robles H, G\u00e1mez-M\u00e9ndez AM, Escalante B. Cyclooxygenase-2 and kidney failure. Prostaglandins Other Lipid Mediat. 2012;98(3\u20134):86\u201390.","journal-title":"Prostaglandins Other Lipid Mediat"},{"issue":"6","key":"5412_CR8","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1016\/j.apsb.2022.01.002","volume":"12","author":"M Zhiran Ju","year":"2022","unstructured":"Zhiran Ju M, Li J, Xu DC, Howell Z, Li F-E, Chen. Recent development on COX-2 inhibitors as promising anti-inflammatory agents: the past 10 years. Acta Pharm Sinica B. 2022;12(6):2790\u2013807.","journal-title":"Acta Pharm Sinica B"},{"key":"5412_CR9","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3389\/fphys.2020.00172","volume":"11","author":"DB Peruchetti","year":"2020","unstructured":"Peruchetti DB, Silva-Filho JL, Silva-Aguiar RP, Teixeira DE, Takiya CM, Souza MC, Henriques MDG, Pinheiro AAS, Caruso-Neves C. IL-4 receptor \u03b1 chain protects the kidney against tubule-interstitial injury induced by albumin overload. Front Physiol. 2020;11:172.","journal-title":"Front Physiol"},{"issue":"25","key":"5412_CR10","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1056\/NEJMra022296","volume":"348","author":"BG Hudson","year":"2003","unstructured":"Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG. Alport\u2019s syndrome, Goodpasture\u2019s syndrome, and type IV collagen. N Engl J Med. 2003;348(25):2543\u201356.","journal-title":"N Engl J Med"},{"key":"5412_CR11","doi-asserted-by":"publisher","first-page":"5174","DOI":"10.2741\/3073","volume":"13","author":"K Hu","year":"2008","unstructured":"Hu K, Mars WM, Liu Y. Novel actions of tissue-type plasminogen activator in chronic kidney disease. Front Biosci. 2008;13:5174\u201386.","journal-title":"Front Biosci"},{"issue":"1","key":"5412_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.23876\/j.krcp.21.222","volume":"41","author":"HAM Mutsaers","year":"2022","unstructured":"Mutsaers HAM, N\u00f8rregaard R. Prostaglandin E2 receptors as therapeutic targets in renal fibrosis. Kidney Res Clin Pract. 2022;41(1):4\u201313.","journal-title":"Kidney Res Clin Pract"},{"key":"5412_CR13","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00467-020-04819-6","volume":"36","author":"E Clifford","year":"2021","unstructured":"Clifford E, Kashtan1 & Oliver Gross. Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults\u2013an update for 2020. Pediatr Nephrol. 2021;36:711\u20139. https:\/\/doi.org\/10.1007\/s00467-020-04819-6","journal-title":"Pediatr Nephrol"},{"key":"5412_CR14","doi-asserted-by":"crossref","unstructured":"Robert G, Fassett GC, Gobe JM, Peake, Jeff S. Coombes. Omega-3 polyunsaturated fatty acids in the treatment of kidney disease. Am J Kidney Dis. 2010, Volume 56, Issue 4, Pages 728-742.  https:\/\/doi.org\/10.1053\/j.ajkd.2010.03.009","DOI":"10.1053\/j.ajkd.2010.03.009"},{"key":"5412_CR15","unstructured":"Watson S, Padala SA, Hashmi MF et al. Alport Syndrome. [Updated 2023 Aug 14]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470419\/"},{"issue":"9","key":"5412_CR16","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.2215\/CJN.00580116","volume":"11","author":"J Savige","year":"2016","unstructured":"Savige J, Colville D, Rheault M, Gear S, Lennon R, Lagas S, Finlay M, Flinter F. Alport syndrome in women and girls. Clin J Am Soc Nephrol. 2016;11(9):1713\u201320.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"5412_CR17","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/ki.1985.63","volume":"27","author":"J Feingold","year":"1985","unstructured":"Feingold J, Bois E, Chompret A, Broyer M, Gubler MC, Gr\u00fcnfeld JP. Genetic heterogeneity of Alport syndrome. Kidney Int. 1985;27(4):672\u20137.","journal-title":"Kidney Int"},{"issue":"6","key":"5412_CR18","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/j.kint.2020.10.040","volume":"99","author":"AM \u017burowska","year":"2021","unstructured":"\u017burowska AM, Bielska O, Daca-Roszak P, Jankowski M, Szczepa\u0144ska M, Roszkowska-Bjanid D, et al. Mild X-linked Alport syndrome due to the COL4A5 G624D variant originating in the middle ages is predominant in Central\/East Europe and causes kidney failure in midlife. Kidney Int. 2021;99(6):1451\u20138.","journal-title":"Kidney Int"},{"issue":"1","key":"5412_CR19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2215\/CJN.04230321","volume":"17","author":"J Savige","year":"2022","unstructured":"Savige J, Lipska-Zietkiewicz BS, Watson E, Hertz JM, Deltas C, Mari F, Hilbert P, et al. Guidelines for genetic testing and management of Alport syndrome. Clin J Am Soc Nephrol. 2022;17(1):143\u201354.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"5412_CR20","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1681\/ASN.2021040577","volume":"33","author":"AA Widjaja","year":"2022","unstructured":"Widjaja AA, Shekeran SG, Adami E, Ting JGW, Tan J, Viswanathan S, Lim SY, Tan PH, H\u00fcbner N, Coffman T, Cook SA. A neutralizing IL-11 antibody improves renal function and increases lifespan in a mouse model of Alport syndrome. J Am Soc Nephrol. 2022;33(4):718\u201330.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"5412_CR21","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1053\/j.ajkd.2020.03.026","volume":"77","author":"CE Kashtan","year":"2021","unstructured":"Kashtan CE. Alport syndrome: achieving early diagnosis and treatment. Am J Kidney Dis. 2021;77(2):272\u20139.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"5412_CR22","first-page":"136","volume":"76","author":"FI Moushira Zaki","year":"2022","unstructured":"Moushira Zaki FI, Fadel SE, El-Toukhy ER, Youness A, Selim, Mohamed EL-S, Hala T, El-Bassyouni. Netrin-1 and cyclophilin A (CypA): biomarkers of inflammation and kidney injury in Alport syndrome: a pilot study. N Z J Med Lab Sci. 2022;76(3):136\u20138.","journal-title":"N Z J Med Lab Sci"},{"key":"5412_CR23","doi-asserted-by":"crossref","unstructured":"Jia Z, Zhang Y, Ding G, Heiney KM, Huang S, Zhang A. Role of COX-2\/mPGES-1\/prostaglandin E2 cascade in kidney injury. Mediators Inflamm. 2015;2015:147894.","DOI":"10.1155\/2015\/147894"},{"key":"5412_CR24","doi-asserted-by":"publisher","first-page":"1229636","DOI":"10.3389\/fimmu.2023.1229636","volume":"30","author":"H Li","year":"2023","unstructured":"Li H, Li M, Liu C, He P, Dong A, Dong S, Zhang M. Causal effects of systemic inflammatory regulators on chronic kidney diseases and renal function: a bidirectional Mendelian randomization study. Front Immunol. 2023;30:14:1229636.","journal-title":"Front Immunol"},{"key":"5412_CR25","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41392-022-01036-5","volume":"7","author":"Q Yuan","year":"2022","unstructured":"Yuan Q, Tang B, Zhang C. Signaling pathways of chronic kidney diseases, implications for therapeutics. Sig Transduct Target Ther. 2022;7:182.","journal-title":"Sig Transduct Target Ther"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-025-05412-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-025-05412-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-025-05412-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T04:52:33Z","timestamp":1737694353000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-025-05412-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5412"],"URL":"https:\/\/doi.org\/10.1186\/s12887-025-05412-2","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"2 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The National Research Centre Ethical Research Committee (Number 013100324 date 26\/3\/2024) certified that the study\u2019s laboratory procedures and recruitment practices adhered to the Declaration of Helsinki. All of the new mothers voluntarily signed the informed consent form to participate in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}